progressing on the comparator. P006 A 36 m July 2016 KEYNOTE006 is Multicentre, 645 an ongoing Randomised pts; study of two Controlled, doses of Three-Arm, pembrolizumab 831 Phase III (10 mg/kg Q2W pts Study to or 10 mg/kg Evaluate the Q3W) versus Safety and ipilimumab. Of Efficacy of note, cross over Two Dosing to Schedules of pembrolizumab MK-3475 is not permitted Compared in this study to compared to Ipilimumab KEYNOTE002 in Patients above. A total of with 556 patients Advanced have been Melanoma; treated with Phase III pembrolizumab in KEYNOTE006. NSCLC P001 Phase I 24 m December KEYNOTE001 is Parts Study of 1246 2016 the phase I C and Single Agent pts study that F MK-3475 in included two Patients cohorts with 1191 with NSCLC patients. pts Progressive Cohort C was Locally (for the preliminary Advanced or all NSCLC 3rd line Metastatic P001) cohort. Cohort F Carcinoma, includes NSCLC Melanoma, patients with and Non- various lines of Small Cell therapy Lung including Carcinoma; patients Phase I without prior chemotherapy. A total of 549 NSCLC patients have been treated in
progressing on the comparator. P006 A Multicentre, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma; Phase III 645 pts; 831 pts 36 m July 2016 KEYNOTE006 is an ongoing study of two doses of pembrolizumab (10 mg/kg Q2W or 10 mg/kg Q3W) versus ipilimumab. Of note, cross over to pembrolizumab is not permitted in this study compared to KEYNOTE002 above. A total of 556 patients have been treated with pembrolizumab in KEYNOTE006. NSCLC P001 Parts C and F Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non- Small Cell Lung Carcinoma; Phase I 1246 pts 1191 pts (for all P001) 24 m December 2016 KEYNOTE001 is the phase I study that included two cohorts with NSCLC patients. Cohort C was the preliminary NSCLC 3rd line cohort. Cohort F includes NSCLC patients with various lines of therapy including patients without prior chemotherapy. A total of 549 NSCLC patients have been treated in Randomised
auspar-pembrolizumab-rch-161014.docx